Molecule
Desloratadine is a histamine-1 receptor antagonist indicated for seasonal Allergic Rhinitis, among other approved uses. It is available as tablets, orally disintegrating tablets and oral solution. MedsAcross supplies Desloratadine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
CLARINEX is a histamine-1 (H1) receptor antagonist indicated for: Seasonal Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 2 years of age and older. Perennial Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 6 months of age and older. Chronic Idiopathic Urticaria: symptomatic relief of pruritus, reduction in the number of hives, and size of hives in patients 6 months of age and older.
Source: US FDA prescribing information
Desloratadine is a long-acting tricyclic histamine antagonist with selective H 1 -receptor histamine antagonist activity. Receptor binding data indicates that at a concentration of 2–3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H 1 -receptor. Desloratadine inhibited histamine release from human mast cells in vitro. Results of a radiolabeled tissue distribution study in rats and a radioligand H 1 -receptor binding study in guinea pigs showed that desloratadine did not readily cross the blood brain barrier. The clinical significance of this finding is unknown.
Source: US FDA prescribing information
Although the oral solution and the orally disintegrating tablet formulation of desloratadine may be available in the marketplace, CLARINEX ® Oral Solution and CLARINEX ® RediTabs ® Tablets are no longer marketed. CLARINEX Tablets, Oral Solution, or RediTabs Tablets may be taken without regard to meals. Place CLARINEX (desloratadine) RediTabs Tablets on the tongue and allow to disintegrate before swallowing. Tablet disintegration occurs rapidly. Administer with or without water. Take tablet immediately after opening the blister. The age-appropriate dose of CLARINEX Oral Solution should be administered with a commercially available measuring dropper or syringe that is calibrated to deliver 2 mL and 2.5 mL (½ teaspoon).
Source: US FDA prescribing information
CLARINEX Tablets, RediTabs, and Oral Solution are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients or to loratadine. Hypersensitivity
Source: US FDA prescribing information
Hypersensitivity reactions including rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis have been reported. In such cases, stop CLARINEX at once and consider alternative treatments.
Source: US FDA prescribing information
The following adverse reactions are discussed in greater detail in other sections of the label: Hypersensitivity reactions. The most common adverse reactions (reported in ≥2% of adult and adolescent patients with allergic rhinitis and greater than placebo) were pharyngitis, dry mouth, myalgia, fatigue, somnolence, dysmenorrhea.
Source: US FDA prescribing information
Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine.
Source: US FDA prescribing information
Store at 25°C (77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Avoid exposure at or above 30°C (86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
5 presentations of Desloratadine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Desloratadine 5 mg tabletOralGeneric name | — | US FDA | Available on request |
| Clarinex 5 mg tabletOral | Organon | US FDA | Available on request |
| Desloratadine 2.5 mg orally disintegrating tabletOralGeneric name | — | US FDA | Available on request |
| Desloratadine 5 mg orally disintegrating tabletOralGeneric name | — | US FDA | Available on request |
| Desloratadine 0.5 mg/mL oral solutionOralGeneric name | — | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Desloratadine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 5 presentations of Desloratadine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Desloratadine, including Clarinex.
Yes. The US FDA first approved Desloratadine on 21 December 2001, according to Drugs@FDA.
Yes. Desloratadine has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Desloratadine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Desloratadine is classified under ATC code R06AX27 (Desloratadine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.